- Shares of U.S. vaccine maker Novavax ( NASDAQ: NVAX ) on Tuesday closed about 6% higher , ending an eight-session losing streak which included a ~27% drop in the last three days.
- On Monday, the stock ended 13.3% in the red , after JPMorgan downgraded the Maryland-based COVID-19 vaccine maker to underweight from neutral, citing, among other things, the company's long-term outlook.
- The stock fell another ~10% yesterday. It has been under pressure since reporting a big Q2 sales miss in Aug., having shed 53.2% since.
- Novavax ( NVAX ) entered the COVID-19 vaccine space quite late, with U.S. regulators clearing its protein-based shot only in July and European regulators following suit. However, as the pandemic waned, its vaccine sales came under pressure.
- On Tuesday, the shares rebounded to close 6.2% higher at $20.04.
- The company earlier in the day said an initial 1M doses of its COVID-19 vaccine was now available for use in the United Kingdom.
- Throughout Sept., the company has received approvals and expanded approvals for its COVID-19 shot in various countries for use in several age groups, including Taiwan, Israel , South Africa and the European Union .
For further details see:
Novavax stock ends 6% higher, snaps eight-day losing streak amid waning pandemic